Member Info for Merchantbanker

We don't need exclusivity we can only make and sell a fraction of what the demand will be

CK didn't drop the share price. Any one trying to buy on the drop knows how manufactured it was

Impossible to buy

It really isn't a difficult stock to understand or work out what it will be worth. A lot of people don't believe it because they have heard it with many stocks and it hasn't happened. But it's so obvious this is one of the ones that will come good. By the time some people realise it it will be multiples of the price.

97.7% is as good as. Notre there are further independent reviews going on. This is huge news, because many other test have been found out when put through independent review, whereas UK RTC has held up against expectation.

£3 is by no means a long way off.

UK RTC and Visitect antibody test could get it there alone.
Antigen test on top of the above most likely will get it there
Any news on plans to further increase capacity then its anyone's guess how high this can go.
All these things could happen any day

93 to to sell. The £1 could be in reach today

90s here! Didn’t expect it by 8.05!!

Really should be 90s minimum today

One more time.... reasons to buy/hold

UK RTC - Could say the flagship product that will make the front page
Approved for professional use
ABC-19 branded, with website and social media presence
Awaiting MHRA approval after Ulster usability study some weeks ago now
Exceptional performance
MOU expires next week and we except a long term supply agreement
200k per week committed per MOU - look out for an increase
Likely linked to UK Gov policy
Expecting mass testing with tests sent to every household - boots/amazon
Link to testing app and NHS data
Global Interest
New report published today validating the test as a competitive alternative to the best lab tests
Hi activity from partners, including deleted UK Government contract tweet from BBI

Mologic Antibody test
Triple antibody lateral flow device for professional use
Only approved test of its kind
Visitect (Mologic branded)
Mologic seeking WHO approval
Excellent performance
Commercialisation expected to have started last month, as evidenced today by a couple of online distributions showing the product for sale
Capacity going to 200k per week

Elisa Antibody test
Good performance
Some local registrations
Need to find out more about approvals and sales

Antigen tests
Elisa Lab test development due any day
Lateral flow test to follow shortly after lab test
Lateral flow used in Heathrow trial
To be branded under the Visitect brand
Evidence of distribution agreements already in place
Higher price than antibody tests therefore profit potential is vast
Potential to be at the front of the race to achieve a self use test

Core business
Visitect CD4 test WHO approval and expect new orders including US interest.
Covid Visitect tests can help with distribution agreement relationships for CD4 tests, in particular in the US where relationships broke down
Orders already in and expected to grow
Only test of its type
Chine food tolerance self test approval overdue
New tests in development with funding for future use of capacity
Already profitable

General
Lateral flow capacity increased to 500k, plan to go to 1m, and looking most likely will be extended further
High recruitment activity evidenced
Excellent cash position with funding for immediate expansion
Zero debt
Low admin expense
Growing evidence of Antibody immunity
Covid highlighting the need for a robust national diagnostics industry, with huge potential for long term growth in supporting the countries health system

I am sure there are many other things that i have missed, but i hope above shows why i wouldn't want to be invested anywhere else at the moment, and anyone not accepting the high share price growth opportunity here has no idea exactly how big this is going to be. Covid has put Omega on the map, and with the profits it will make it can create a monster in this under penetrated diagnostics market.

Not the only one!!!

20x EBITDA would be astronomical!!!
I’ve been using 5X

Fy2 earnings at full capacity would be upwards of £180m

2m maxed out capacity for 2 years would giver them around £300m in free cash flow, so get to 5m capacity talking £750m in free cash flow over a 2 year period. I really thing that even the most bullish supporters really do not understand the significance of the cash flow generation.
There are reports out there saying covid testing will be around for 5 years, even if it starts to slow down after 2. A short delay in development will do no harm to get capacity up now.

Yes but don't miss out on tens of millions of revenue over the next 2 years at the expense of investments that may take significantly longer to generate that level of income. They will have a cash war chest of hundreds of millions if they get Covid tests right. Do whatever development you want with that.

Upomega - yes agree long term, but holding off £3m spend for a few months (i doubt it's all spent from day 1 anyway) they will bank considerably more than £3m over the coming months

Yep Safy - We are recruiting in Littleport too and expanding capacity there too.

Are people starting to understand now what a masterstroke Colin has pulled with Mologic and why 80% of capacity is reserved for Mologic tests.?

My message to Colin - put the 2 new development tests on hold and use that money to increase capacity up to 5m and beyond. It will pay for itself in a matter of weeks.

Just remember if you are going car shopping at the weekend, it's best to make an appointment in advance with Covid and that....!! ;)

"This is the start of the UK’s at-home antibody test kit programme."

UK RTC - Could say the flagship product that will make the front page
Approved for professional use
ABC-19 branded, with website and social media presence
Awaiting MHRA approval after Ulster usability study some weeks ago now
Exceptional performance
MOU expires next week and we except a long term supply agreement
200k per week committed per MOU - look out for an increase
Likely linked to UK Gov policy
Expecting mass testing with tests sent to every household - boots/amazon
Link to testing app and NHS data
Global Interest
New report published today validating the test as a competitive alternative to the best lab tests
Hi activity from partners, including deleted UK Government contract tweet from BBI

Mologic Antibody test
Triple antibody lateral flow device for professional use
Only approved test of its kind
Visitect (Mologic branded)
Mologic seeking WHO approval
Excellent performance
Commercialisation expected to have started last month, as evidenced today by a couple of online distributions showing the product for sale
Capacity going to 200k per week

Elisa Antibody test
Good performance
Some local registrations
Need to find out more about approvals and sales

Antigen tests
Elisa Lab test development due any day
Lateral flow test to follow shortly after lab test
Lateral flow used in Heathrow trial
To be branded under the Visitect brand
Evidence of distribution agreements already in place
Higher price than antibody tests therefore profit potential is vast
Potential to be at the front of the race to achieve a self use test

Core business
Visitect CD4 test WHO approval and expect new orders including US interest.
Covid Visitect tests can help with distribution agreement relationships for CD4 tests, in particular in the US where relationships broke down
Orders already in and expected to grow
Only test of its type
Chine food tolerance self test approval overdue
New tests in development with funding for future use of capacity
Already profitable

General
Lateral flow capacity increased to 500k, plan to go to 1m, and looking most likely will be extended further
High recruitment activity evidenced
Excellent cash position with funding for immediate expansion
Zero debt
Low admin expense
Growing evidence of Antibody immunity
Covid highlighting the need for a robust national diagnostics industry, with huge potential for long term growth in supporting the countries health system

I am sure there are many other things that i have missed, but i hope above shows why i wouldn't want to be invested anywhere else at the moment, and anyone not accepting the high share price growth opportunity here has no idea exactly how big this is going to be. Covid has put Omega on the map, and with the profits it will make it can create a monster in this under penetrated diagnostics market.

Looks like everything is coming together all at once!